MYCOPHENOLATE MOFETIL THERAPY FOR MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS REFRACTORY TO STANDARD TREATMENTS

Abstract

Mycophenolate mofetil, a non-competitive inhibitor of inosine monophosphate dehydrogenase, is a new treatment agent for glomerular diseases. A 22- year-old male patient with resistant membranoproliferative glomerulonephritis was treated with mycophenolate mofetil in combination with lowdose corticosteroid and cyclosporine-A treatment. The treatment resulted in significant reduction in proteinuria and increase in creatinine clearence in 4th month of the' therapy. Although clinical experience in non-transplant uses of mycophenolate mofetil remains anectodal, the drug may be a useful primary or adjunctive therapy in glomerulonephritides.